Clinical trials: Anticoagulant Therapy
Healthy
Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects
This is a single-dose, randomized, double-blind, two-period, two-treatment, two-sequence, crossover, balanced, pharmacodynamic (PD) study with 7 days wash-out period.
- Trial name
- NCT05265676
- Testing
- Enoxaparin Sodium (Venus Remedies Limited), Enoxaparin Sodium (Sanofi)
- Where
- India
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Venus Remedies Limited
Oral Anticoagulant Therapy
Dental Implants in Patients Under Oral Anticoagulant Therapy
This study evaluated the outcomes in the post-operative recovery following dental implant surgery in patients who continued on oral anticoagulated therapy (OAT) with warfarin.
- Trial name
- NCT04846114
- Testing
- Dental implant surgery
- Where
- Argentina
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Jorge Ernesto Aguilar
Under Oral Anticoagulation Patients
Evaluation of the Contribution of a Pre-consultation Questionnaire on the Therapeutic Education
To assess the value of a dedicated knowledge questionnaire, filled by the patient prior consultation. Indeed, it could allow to target specific shortcomings of patients first, and help the cardiologist to prioritize the other…
- Trial name
- EDUCONSULT (NCT02907151)
- Testing
- Survey
- Where
- France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Montpellier
Coronary Artery Disease
Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy
Dual antiplatelet therapy consisting of aspirin and clopidogrel is the cornerstone of treatment for prevention of atherothrombotic events in patients with coronary artery disease (CAD) undergoing percutaneous coronary…
- Trial name
- NCT01852162
- Testing
- Dabigatran
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Florida
Coronary Artery Disease
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations.
- Trial name
- SWAP-AC (NCT04006288)
- Testing
- Clopidogrel, Prasugrel, ticagrelor
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida
Atrial Fibrillation, Left Atrial Appendage Absent
Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery.
- Conditions
- Atrial Fibrillation, Left Atrial Appendage Absent, Anticoagulant Adverse Reaction
- Trial name
- NCT06401616
- Testing
- OAC will be discontinued for the duration of the trial
- Where
- 6 sites in Denmark
- Volunteers
- 1,220 people
- Sponsor
- Odense University Hospital
Anticoagulants
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Single-institution uncontrolled open-label trial.
- Trial name
- NCT05319340
- Testing
- prescribing anticoagulant therapy
- Volunteers
- 1,000 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Venous Thromboembolic Disease
Comparative Study of the Hemorrhagic Risk in Patients Over 75 Years of Age Taking Enoxaparin
Elderly subjects are at greater risk of thrombophlebitis than the general population, but also of bleeding when anticoagulant therapy is initiated.
- Trial name
- ENOX-VTD-H (NCT05150314)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- University Hospital, Strasbourg, France
Covid19, Venous Thromboembolism
Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial
The Michelle trial is expected to provide high-quality evidence around the role of extended thromboprophylaxis in COVID-19 and will help guide medical decisions in clinical practice.
- Trial name
- MICHELLE (NCT04662684)
- Testing
- Rivaroxaban 10 MG
- Where
- Brazil
- Volunteers
- 320 people
- Sponsor
- Science Valley Research Institute
Cancer, Venous Thromboembolism
Management of Recurrent Venous Thromboembolism During Anticoagulant Treatment in Cancer Patients - a Prospective Cohort Study
Objective: To prospectively evaluate clinical outcomes during guideline-recommended LMWH dose escalation for recurrent VTE during LMWH or DOAC treatment for cancer-associated thrombosis.
- Conditions
- Cancer, Venous Thromboembolism, Recurrence
- Trial name
- REDUCE (NCT05229471)
- Where
- 9 sites in Italy, Netherlands and 1 more
- Volunteers
- 220 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Atrial Fibrillation, Venous Thromboembolism
NOACs Use in AF or VTE (SUNSHINE Registry)
The outcomes regiStry for non-vitamin k antagonist oral anticoagUlants treatmeNt in variouS tHrombotIc dIseases for better cliNical practicE (SUNSHINE) is a multicenter, prospective, observational non-interventional…
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Oral Anticoagulant
- Trial name
- NCT05378308
- Testing
- Patients with Atrial Fibrillation (AF) or venous thromboembolism (VTE)
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Henan Provincial People's Hospital
Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB)
FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)
Background Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended for stroke prevention in non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB), Gastrointestinal Hemorrhage (Clinically Important, Upper), Drug-Related Side Effects and Adverse Reactions
- Trial name
- FENOX (NCT07497893)
- Testing
- Fexuprazan, NOAC therapy
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Anticoagulation Treatment
Register for New Oral Anticoagulants
Patients, who are adjusted to a new oral anticoagulant (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) in routine treatment will recorded in this register.
- Trial name
- NOAC (NCT01588119)
- Where
- Germany
- Volunteers
- 5,000 people
- Sponsor
- GWT-TUD GmbH
Venous Thromboembolism
Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement
The purpose of this study is to determine if TAK-442, once daily (QD) or twice daily (BID), is as safe and effective as enoxaparin in preventing the development of blood clots after knee replacement surgery.
- Trial name
- NCT00641732
- Testing
- TAK-442, Enoxaparin
- Where
- 64 sites in United States, Canada
- Volunteers
- 1,045 people
- Sponsor
- Takeda
Atrial Fibrillation, Stroke
Patient Convenience Study (RE-SONANCE)
The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its…
- Trial name
- NCT02684981
- Where
- 12 sites in Austria, Bulgaria and 10 more
- Volunteers
- 9,472 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Embolism, Proximal Deep Vein Thrombosis
Six Years of Follow-up After Idiopathic Venous Throbmoembolism
Beyond the first 6 months of anticoagulation, patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after stopping anticoagulations.
- Trial name
- Padis-Ext (NCT02884934)
- Where
- 10 sites in France
- Volunteers
- 409 people
- Sponsor
- University Hospital, Brest
Stroke, Stroke (in Patients With Atrial Fibrillation)
Thrombolysis in Factor Xa-inhibitors Trial
This study looks at whether stroke patients who take FXa inhibitors (a type of blood thinner) can safely receive clot-busting treatment (IVT).
- Conditions
- Stroke, Stroke (in Patients With Atrial Fibrillation), Ischemic Stroke, Acute Ischemic Stroke
- Trial name
- SIFT (NCT06878066)
- Testing
- thrombolysis therapy
- Where
- 21 sites in Denmark, Norway and 1 more
- Volunteers
- 300 people
- Sponsor
- Guri Hagberg
GastroIntestinal Bleeding, Anticoagulant-induced Bleeding
Anticoagulation After GI Bleeding Pilot Study and Registry
PANTHER-GI Pilot Study will assess the feasibility of a full-scale multicentre cohort management study evaluating the safety of a standardized strategy for resuming direct oral anticoagulants (DOACs) after major DOAC-related…
- Trial name
- PANTHER-GI (NCT05290857)
- Testing
- Restart DOAC within 7 days of clinical hemostasis after GI bleeding, Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Hospital Research Institute
Atrial Fibrillation
Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over
The aim of the study is to compare, in real life, the risk benefit (including both major bleeding and thrombotic events (TE) and death from any cause) associated with direct oral anticoagulants (DOA) and with anti vitamin K (VKA)…
- Trial name
- PRESAGE-ACO (NCT02286414)
- Testing
- Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban, Vitamin K antagonist: warfarin, fluindione, acenocoumarol
- Where
- France
- Volunteers
- 159 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cirrhosis, Portal Vein Thrombosis
Safety of Anticoagulant Therapy After Endoscopic Treatment
The investigators aimed to verify the efficacy and safety of nadroparin calcium warfarin sequential (NWS) anticoagulation therapy after endoscopic therapy in PVT patients with cirrhosis and AVB.
- Conditions
- Cirrhosis, Portal Vein Thrombosis, Esophageal and Gastric Varices, Anticoagulant-induced Bleeding
- Trial name
- NCT04976543
- Testing
- nadroparin calcium-warfarin sequential anticoagulation
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Qilu Hospital of Shandong University